Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">IMWG consensus on maintenance therapy in multiple myeloma</title><author><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name><affiliation><nlm:aff id="aff1">Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria;</nlm:aff></affiliation></author><author><name sortKey="Durie, Brian G M" sort="Durie, Brian G M" uniqKey="Durie B" first="Brian G. M." last="Durie">Brian G. M. Durie</name><affiliation><nlm:aff id="aff2">Southwest Oncology Group, International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA;</nlm:aff></affiliation></author><author><name sortKey="Mccarthy, Philip" sort="Mccarthy, Philip" uniqKey="Mccarthy P" first="Philip" last="Mccarthy">Philip Mccarthy</name><affiliation><nlm:aff id="aff3">Roswell Park Cancer Institute, Buffalo, NY;</nlm:aff></affiliation></author><author><name sortKey="Palumbo, Antonio" sort="Palumbo, Antonio" uniqKey="Palumbo A" first="Antonio" last="Palumbo">Antonio Palumbo</name><affiliation><nlm:aff id="aff4">Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria S. Giovanni Battista, Torino, Italy;</nlm:aff></affiliation></author><author><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jésus" last="San Miguel">Jésus San Miguel</name><affiliation><nlm:aff id="aff5">University Hospital of Salamanca, Salamanca, Spain;</nlm:aff></affiliation></author><author><name sortKey="Barlogie, Bart" sort="Barlogie, Bart" uniqKey="Barlogie B" first="Bart" last="Barlogie">Bart Barlogie</name><affiliation><nlm:aff id="aff6">Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;</nlm:aff></affiliation></author><author><name sortKey="Morgan, Gareth" sort="Morgan, Gareth" uniqKey="Morgan G" first="Gareth" last="Morgan">Gareth Morgan</name><affiliation><nlm:aff id="aff7">Haemato-Oncology Unit, Royal Marsden Hospital, London, United Kingdom;</nlm:aff></affiliation></author><author><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name><affiliation><nlm:aff id="aff8">Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;</nlm:aff></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation><nlm:aff id="aff9">Clinical Haematology/Bone Marrow Transplant Department, Alfred Hospital, Melbourne, Victoria, Australia;</nlm:aff></affiliation></author><author><name sortKey="Andersen, Kenneth C" sort="Andersen, Kenneth C" uniqKey="Andersen K" first="Kenneth C." last="Andersen">Kenneth C. Andersen</name><affiliation><nlm:aff id="aff10">Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;</nlm:aff></affiliation></author><author><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name><affiliation><nlm:aff id="aff11">Department of Hematology, Hospital Claude Huriez, Lille, France;</nlm:aff></affiliation></author><author><name sortKey="Stewart, Keith A" sort="Stewart, Keith A" uniqKey="Stewart K" first="Keith A." last="Stewart">Keith A. Stewart</name><affiliation><nlm:aff id="aff12">Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;</nlm:aff></affiliation></author><author><name sortKey="Einsele, Hermann" sort="Einsele, Hermann" uniqKey="Einsele H" first="Hermann" last="Einsele">Hermann Einsele</name><affiliation><nlm:aff id="aff13">Department of Internal Medicine II, University Hospital, Würzburg, Germany;</nlm:aff></affiliation></author><author><name sortKey="Mateos, Maria Victoria" sort="Mateos, Maria Victoria" uniqKey="Mateos M" first="Maria-Victoria" last="Mateos">Maria-Victoria Mateos</name><affiliation><nlm:aff id="aff5">University Hospital of Salamanca, Salamanca, Spain;</nlm:aff></affiliation></author><author><name sortKey="Wijermans, Pierre" sort="Wijermans, Pierre" uniqKey="Wijermans P" first="Pierre" last="Wijermans">Pierre Wijermans</name><affiliation><nlm:aff id="aff14">Haga Hospital, The Hague, The Netherlands;</nlm:aff></affiliation></author><author><name sortKey="Waage, Anders" sort="Waage, Anders" uniqKey="Waage A" first="Anders" last="Waage">Anders Waage</name><affiliation><nlm:aff id="aff15">Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway;</nlm:aff></affiliation></author><author><name sortKey="Beksac, Meral" sort="Beksac, Meral" uniqKey="Beksac M" first="Meral" last="Beksac">Meral Beksac</name><affiliation><nlm:aff id="aff16">Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;</nlm:aff></affiliation></author><author><name sortKey="Richardson, Paul G" sort="Richardson, Paul G" uniqKey="Richardson P" first="Paul G." last="Richardson">Paul G. Richardson</name><affiliation><nlm:aff id="aff10">Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;</nlm:aff></affiliation></author><author><name sortKey="Hulin, Cyrille" sort="Hulin, Cyrille" uniqKey="Hulin C" first="Cyrille" last="Hulin">Cyrille Hulin</name><affiliation><nlm:aff id="aff17">Hematology Department, University Hospital, Nancy, France;</nlm:aff></affiliation></author><author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name><affiliation><nlm:aff id="aff18">Weill Cornell Medical College, New York, NY;</nlm:aff></affiliation></author><author><name sortKey="Lokhorst, Henk" sort="Lokhorst, Henk" uniqKey="Lokhorst H" first="Henk" last="Lokhorst">Henk Lokhorst</name><affiliation><nlm:aff id="aff19">University Medical Center, Utrecht, The Netherlands;</nlm:aff></affiliation></author><author><name sortKey="Landgren, Ola" sort="Landgren, Ola" uniqKey="Landgren O" first="Ola" last="Landgren">Ola Landgren</name><affiliation><nlm:aff id="aff20">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Bergsagel, P Leif" sort="Bergsagel, P Leif" uniqKey="Bergsagel P" first="P. Leif" last="Bergsagel">P. Leif Bergsagel</name><affiliation><nlm:aff id="aff12">Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;</nlm:aff></affiliation></author><author><name sortKey="Orlowski, Robert" sort="Orlowski, Robert" uniqKey="Orlowski R" first="Robert" last="Orlowski">Robert Orlowski</name><affiliation><nlm:aff id="aff21">Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff></affiliation></author><author><name sortKey="Hinke, Axel" sort="Hinke, Axel" uniqKey="Hinke A" first="Axel" last="Hinke">Axel Hinke</name><affiliation><nlm:aff id="aff22">WISP Research Institute, Langenfeld, Germany;</nlm:aff></affiliation></author><author><name sortKey="Cavo, Michele" sort="Cavo, Michele" uniqKey="Cavo M" first="Michele" last="Cavo">Michele Cavo</name><affiliation><nlm:aff wicri:cut="; and" id="aff23">Seràgnoli Institute of Haematology, Bologna School of Medicine, S. Orsola's University Hospital, Bologna, Italy</nlm:aff></affiliation></author><author><name sortKey="Attal, Michel" sort="Attal, Michel" uniqKey="Attal M" first="Michel" last="Attal">Michel Attal</name><affiliation><nlm:aff id="aff24">Service d'Hématologie, Hospital Purpan, Toulouse, France</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22271445</idno><idno type="pmc">3321864</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321864</idno><idno type="RBID">PMC:3321864</idno><idno type="doi">10.1182/blood-2011-11-374249</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">002E73</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002E73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">IMWG consensus on maintenance therapy in multiple myeloma</title><author><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name><affiliation><nlm:aff id="aff1">Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria;</nlm:aff></affiliation></author><author><name sortKey="Durie, Brian G M" sort="Durie, Brian G M" uniqKey="Durie B" first="Brian G. M." last="Durie">Brian G. M. Durie</name><affiliation><nlm:aff id="aff2">Southwest Oncology Group, International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA;</nlm:aff></affiliation></author><author><name sortKey="Mccarthy, Philip" sort="Mccarthy, Philip" uniqKey="Mccarthy P" first="Philip" last="Mccarthy">Philip Mccarthy</name><affiliation><nlm:aff id="aff3">Roswell Park Cancer Institute, Buffalo, NY;</nlm:aff></affiliation></author><author><name sortKey="Palumbo, Antonio" sort="Palumbo, Antonio" uniqKey="Palumbo A" first="Antonio" last="Palumbo">Antonio Palumbo</name><affiliation><nlm:aff id="aff4">Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria S. Giovanni Battista, Torino, Italy;</nlm:aff></affiliation></author><author><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jésus" last="San Miguel">Jésus San Miguel</name><affiliation><nlm:aff id="aff5">University Hospital of Salamanca, Salamanca, Spain;</nlm:aff></affiliation></author><author><name sortKey="Barlogie, Bart" sort="Barlogie, Bart" uniqKey="Barlogie B" first="Bart" last="Barlogie">Bart Barlogie</name><affiliation><nlm:aff id="aff6">Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;</nlm:aff></affiliation></author><author><name sortKey="Morgan, Gareth" sort="Morgan, Gareth" uniqKey="Morgan G" first="Gareth" last="Morgan">Gareth Morgan</name><affiliation><nlm:aff id="aff7">Haemato-Oncology Unit, Royal Marsden Hospital, London, United Kingdom;</nlm:aff></affiliation></author><author><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name><affiliation><nlm:aff id="aff8">Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;</nlm:aff></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation><nlm:aff id="aff9">Clinical Haematology/Bone Marrow Transplant Department, Alfred Hospital, Melbourne, Victoria, Australia;</nlm:aff></affiliation></author><author><name sortKey="Andersen, Kenneth C" sort="Andersen, Kenneth C" uniqKey="Andersen K" first="Kenneth C." last="Andersen">Kenneth C. Andersen</name><affiliation><nlm:aff id="aff10">Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;</nlm:aff></affiliation></author><author><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name><affiliation><nlm:aff id="aff11">Department of Hematology, Hospital Claude Huriez, Lille, France;</nlm:aff></affiliation></author><author><name sortKey="Stewart, Keith A" sort="Stewart, Keith A" uniqKey="Stewart K" first="Keith A." last="Stewart">Keith A. Stewart</name><affiliation><nlm:aff id="aff12">Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;</nlm:aff></affiliation></author><author><name sortKey="Einsele, Hermann" sort="Einsele, Hermann" uniqKey="Einsele H" first="Hermann" last="Einsele">Hermann Einsele</name><affiliation><nlm:aff id="aff13">Department of Internal Medicine II, University Hospital, Würzburg, Germany;</nlm:aff></affiliation></author><author><name sortKey="Mateos, Maria Victoria" sort="Mateos, Maria Victoria" uniqKey="Mateos M" first="Maria-Victoria" last="Mateos">Maria-Victoria Mateos</name><affiliation><nlm:aff id="aff5">University Hospital of Salamanca, Salamanca, Spain;</nlm:aff></affiliation></author><author><name sortKey="Wijermans, Pierre" sort="Wijermans, Pierre" uniqKey="Wijermans P" first="Pierre" last="Wijermans">Pierre Wijermans</name><affiliation><nlm:aff id="aff14">Haga Hospital, The Hague, The Netherlands;</nlm:aff></affiliation></author><author><name sortKey="Waage, Anders" sort="Waage, Anders" uniqKey="Waage A" first="Anders" last="Waage">Anders Waage</name><affiliation><nlm:aff id="aff15">Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway;</nlm:aff></affiliation></author><author><name sortKey="Beksac, Meral" sort="Beksac, Meral" uniqKey="Beksac M" first="Meral" last="Beksac">Meral Beksac</name><affiliation><nlm:aff id="aff16">Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;</nlm:aff></affiliation></author><author><name sortKey="Richardson, Paul G" sort="Richardson, Paul G" uniqKey="Richardson P" first="Paul G." last="Richardson">Paul G. Richardson</name><affiliation><nlm:aff id="aff10">Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;</nlm:aff></affiliation></author><author><name sortKey="Hulin, Cyrille" sort="Hulin, Cyrille" uniqKey="Hulin C" first="Cyrille" last="Hulin">Cyrille Hulin</name><affiliation><nlm:aff id="aff17">Hematology Department, University Hospital, Nancy, France;</nlm:aff></affiliation></author><author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name><affiliation><nlm:aff id="aff18">Weill Cornell Medical College, New York, NY;</nlm:aff></affiliation></author><author><name sortKey="Lokhorst, Henk" sort="Lokhorst, Henk" uniqKey="Lokhorst H" first="Henk" last="Lokhorst">Henk Lokhorst</name><affiliation><nlm:aff id="aff19">University Medical Center, Utrecht, The Netherlands;</nlm:aff></affiliation></author><author><name sortKey="Landgren, Ola" sort="Landgren, Ola" uniqKey="Landgren O" first="Ola" last="Landgren">Ola Landgren</name><affiliation><nlm:aff id="aff20">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Bergsagel, P Leif" sort="Bergsagel, P Leif" uniqKey="Bergsagel P" first="P. Leif" last="Bergsagel">P. Leif Bergsagel</name><affiliation><nlm:aff id="aff12">Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;</nlm:aff></affiliation></author><author><name sortKey="Orlowski, Robert" sort="Orlowski, Robert" uniqKey="Orlowski R" first="Robert" last="Orlowski">Robert Orlowski</name><affiliation><nlm:aff id="aff21">Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff></affiliation></author><author><name sortKey="Hinke, Axel" sort="Hinke, Axel" uniqKey="Hinke A" first="Axel" last="Hinke">Axel Hinke</name><affiliation><nlm:aff id="aff22">WISP Research Institute, Langenfeld, Germany;</nlm:aff></affiliation></author><author><name sortKey="Cavo, Michele" sort="Cavo, Michele" uniqKey="Cavo M" first="Michele" last="Cavo">Michele Cavo</name><affiliation><nlm:aff wicri:cut="; and" id="aff23">Seràgnoli Institute of Haematology, Bologna School of Medicine, S. Orsola's University Hospital, Bologna, Italy</nlm:aff></affiliation></author><author><name sortKey="Attal, Michel" sort="Attal, Michel" uniqKey="Attal M" first="Michel" last="Attal">Michel Attal</name><affiliation><nlm:aff id="aff24">Service d'Hématologie, Hospital Purpan, Toulouse, France</nlm:aff></affiliation></author></analytic><series><title level="j">Blood</title><idno type="ISSN">0006-4971</idno><idno type="eISSN">1528-0020</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review the relevant data. Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival (PFS) significantly in all 6 studies and overall survival (OS) in 3 of them. In elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. A meta-analysis revealed a significant risk reduction for PFS/event-free survival and death. The role of thalidomide maintenance after melphalan, prednisone, and thalidomide is not well established. Two trials with lenalidomide maintenance treatment after autologous stem cell transplantation and one study after conventional melphalan, prednisone, and lenalidomide induction therapy showed a significant risk reduction for PFS and an increase in OS in one of the transplant trials. Maintenance therapy with single-agent bortezomib or in combination with thalidomide or prednisone has been studied. One trial revealed a significantly increased OS with a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction and thalidomide maintenance treatment. Maintenance treatment can be associated with significant side effects, and none of the drugs evaluated is approved for maintenance therapy. Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Blood</journal-id><journal-id journal-id-type="iso-abbrev">Blood</journal-id><journal-id journal-id-type="hwp">bloodjournal</journal-id><journal-id journal-id-type="pmc">blood</journal-id><journal-id journal-id-type="publisher-id">Blood</journal-id><journal-title-group><journal-title>Blood</journal-title></journal-title-group><issn pub-type="ppub">0006-4971</issn><issn pub-type="epub">1528-0020</issn><publisher><publisher-name>American Society of Hematology</publisher-name><publisher-loc>Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22271445</article-id><article-id pub-id-type="pmc">3321864</article-id><article-id pub-id-type="publisher-id">2011/374249</article-id><article-id pub-id-type="doi">10.1182/blood-2011-11-374249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>IMWG consensus on maintenance therapy in multiple myeloma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ludwig</surname><given-names>Heinz</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Durie</surname><given-names>Brian G. M.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McCarthy</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Palumbo</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>San Miguel</surname><given-names>Jésus</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Barlogie</surname><given-names>Bart</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Morgan</surname><given-names>Gareth</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Sonneveld</surname><given-names>Pieter</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Spencer</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Andersen</surname><given-names>Kenneth C.</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Facon</surname><given-names>Thierry</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Keith A.</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Einsele</surname><given-names>Hermann</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Mateos</surname><given-names>Maria-Victoria</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wijermans</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Waage</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Beksac</surname><given-names>Meral</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Paul G.</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Hulin</surname><given-names>Cyrille</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Niesvizky</surname><given-names>Ruben</given-names></name><xref ref-type="aff" rid="aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Lokhorst</surname><given-names>Henk</given-names></name><xref ref-type="aff" rid="aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Landgren</surname><given-names>Ola</given-names></name><xref ref-type="aff" rid="aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Bergsagel</surname><given-names>P. Leif</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Orlowski</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Hinke</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Cavo</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Attal</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="aff24">24</xref></contrib><on-behalf-of>on behalf of the International Myeloma Working Group</on-behalf-of><aff id="aff1"><label>1</label>Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria;</aff><aff id="aff2"><label>2</label>Southwest Oncology Group, International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA;</aff><aff id="aff3"><label>3</label>Roswell Park Cancer Institute, Buffalo, NY;</aff><aff id="aff4"><label>4</label>Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria S. Giovanni Battista, Torino, Italy;</aff><aff id="aff5"><label>5</label>University Hospital of Salamanca, Salamanca, Spain;</aff><aff id="aff6"><label>6</label>Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;</aff><aff id="aff7"><label>7</label>Haemato-Oncology Unit, Royal Marsden Hospital, London, United Kingdom;</aff><aff id="aff8"><label>8</label>Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;</aff><aff id="aff9"><label>9</label>Clinical Haematology/Bone Marrow Transplant Department, Alfred Hospital, Melbourne, Victoria, Australia;</aff><aff id="aff10"><label>10</label>Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;</aff><aff id="aff11"><label>11</label>Department of Hematology, Hospital Claude Huriez, Lille, France;</aff><aff id="aff12"><label>12</label>Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;</aff><aff id="aff13"><label>13</label>Department of Internal Medicine II, University Hospital, Würzburg, Germany;</aff><aff id="aff14"><label>14</label>Haga Hospital, The Hague, The Netherlands;</aff><aff id="aff15"><label>15</label>Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway;</aff><aff id="aff16"><label>16</label>Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;</aff><aff id="aff17"><label>17</label>Hematology Department, University Hospital, Nancy, France;</aff><aff id="aff18"><label>18</label>Weill Cornell Medical College, New York, NY;</aff><aff id="aff19"><label>19</label>University Medical Center, Utrecht, The Netherlands;</aff><aff id="aff20"><label>20</label>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</aff><aff id="aff21"><label>21</label>Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX;</aff><aff id="aff22"><label>22</label>WISP Research Institute, Langenfeld, Germany;</aff><aff id="aff23"><label>23</label>Seràgnoli Institute of Haematology, Bologna School of Medicine, S. Orsola's University Hospital, Bologna, Italy; and</aff><aff id="aff24"><label>24</label>Service d'Hématologie, Hospital Purpan, Toulouse, France</aff></contrib-group><pub-date pub-type="ppub"><day>29</day><month>3</month><year>2012</year></pub-date><pub-date pub-type="epreprint"><day>23</day><month>1</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>3</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 12 months and 0 days and was based on the
<volume>119</volume><issue>13</issue><fpage>3003</fpage><lpage>3015</lpage><history><date date-type="received"><day>9</day><month>11</month><year>2011</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2012</year></date></history><permissions><copyright-statement>© 2012 by The American Society of Hematology</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zh801312003003.pdf"></self-uri><abstract><p>Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review the relevant data. Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival (PFS) significantly in all 6 studies and overall survival (OS) in 3 of them. In elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. A meta-analysis revealed a significant risk reduction for PFS/event-free survival and death. The role of thalidomide maintenance after melphalan, prednisone, and thalidomide is not well established. Two trials with lenalidomide maintenance treatment after autologous stem cell transplantation and one study after conventional melphalan, prednisone, and lenalidomide induction therapy showed a significant risk reduction for PFS and an increase in OS in one of the transplant trials. Maintenance therapy with single-agent bortezomib or in combination with thalidomide or prednisone has been studied. One trial revealed a significantly increased OS with a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction and thalidomide maintenance treatment. Maintenance treatment can be associated with significant side effects, and none of the drugs evaluated is approved for maintenance therapy. Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002E73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |